Dentacilina

Dentacilina may be available in the countries listed below.

Ingredient matches for Dentacilina

Ampicillin

Ampicillin is reported as an ingredient of Dentacilina in the following countries:

• Peru

International Drug Name Search

Codeine

In some countries, this medicine may only be approved for veterinary use.

In the US, Codeine (codeine systemic) is a member of the following drug classes: antitussives, narcotic analgesics and is used to treat Cough, Diarrhea and Pain.

US matches:

• Codeine


• Codeine Phosphate Soluble Tablets


• Codeine Phosphate Solution


• Codeine Sulfate


• Codeine/Chlorcyclizine/Pseudoephedrine Liquid


• Codeine/Diphenhydramine/Phenylephrine Solution


• Codeine/Guaifenesin


• Codeine/Guaifenesin Liquid


• Codeine/Guaifenesin/Phenylephrine Liquid


• Codeine/Guaifenesin/Pseudoephedrine


• Codeine/Guaifenesin/Pseudoephedrine Liquid


• Codeine/Phenylephrine/Promethazine Syrup


• Codeine/Phenylephrine/Pyrilamine Syrup


• Codeine/Pseudoephedrine


• Codeine/Pyrilamine Syrup


• Codeine Phosphate-Promethazine HCl


• Codeine and guaifenesin


• Codeine and phenylephrine


• Codeine and promethazine


• Codeine, dexchlorpheniramine, and phenylephrine


• Codeine, diphenhydramine, and phenylephrine


• Codeine, guaifenesin, and phenylephrine


• Codeine, guaifenesin, and pseudoephedrine


• Codeine, phenylephrine, and promethazine


• Codeine Phosphate


• Codeine Phosphate and Guaifenesin

UK matches:

• Codeine Phosphate Tablets 15mg, 30mg, 60mg (Actavis UK Ltd)
• Codeine Phosphate Tablets BP (Wockhardt UK Ltd)
• Codeine Linctus BP (SPC)

Scheme

BAN

ATC (Anatomical Therapeutic Chemical Classification)

R05DA04

CAS registry number (Chemical Abstracts Service)

0000076-57-3

Chemical Formula

C18-H21-N-O3

Molecular Weight

299

Therapeutic Categories

Cough suppressant

Opioid analgesic

Chemical Names

Morphin-7-en-6α-ol, 4,5α-epoxy-3-methoxy-17-methyl-,

Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5α,6α)-

Foreign Names

• Codeinum (Latin)
• Codein (German)
• Codeine (French)

Generic Names

• Codeine (OS: BAN)
• Codéine (OS: DCF)
• 3-Methylmorphin (IS)
• Morphine 3-methylether (IS)
• Codeine (PH: BP 2007, USP 32)
• Codein Hydrochloride (OS: BANM)
• Codéine (chlorhydrate de) dihydraté (PH: Ph. Eur. 6)
• Codeine Hydrochloride (PH: BP 2010)
• Codeine Hydrochloride Dihydrate (PH: Ph. Eur. 6)
• Codeinhydrochlorid-Dihydrat (PH: Ph. Eur. 6)
• Codeini hydrochloridum dihydricum (PH: Ph. Eur. 6)
• Morphin-3-methylether (IS)
• Codein (PH: Ph. Eur. 6)
• Codeine (PH: BP 2010, USP 30, Ph. Eur. 6)
• Codéine (PH: Ph. Eur. 6)
• Codeine Monohydrate (PH: Ph. Int. 4)
• Codeinum (PH: Ph. Eur. 6)
• Codeinum monohydricum (PH: Ph. Int. 4)
• Codeine Phosphate (OS: JAN, BANM)
• Codéine (phosphate de) hémihydraté (PH: Ph. Eur. 6)
• Codeine Phosphate (PH: BP 2010, Ph. Int. 4, USP 32, JP XIV)
• Codeine Phosphate Hemihydrate (PH: Ph. Eur. 6)
• Codeini phosphas (PH: Ph. Int. 4)
• Codeini phosphas hemihydricus (PH: Ph. Eur. 6)
• Codeinphosphat-Hemihydrat (PH: Ph. Eur. 6)
• Codeine Polistirex (OS: USAN)
• Codein sulfate (PH: USP 32)

Brand Names

• Apiretal Codeina (Codeine and Paracetamol)
  Ern, Spain



• Bronchocanis (Codeine and Chlorphenamin (veterinary use))
  Véto-Centre, France



• Broncho-Pectoralis Codeine
  Medgenix, Belgium



• Calyptin-codein (Codeine and Eucalyptol)
  F.T. Pharma, Vietnam



• Codenfan
  Bouchara-Recordati, Tunisia



• Codifarma
  Farmindustria, Peru



• Codilusa
  Lusa, Peru



• Codipertussin
  Astellas, Austria



• Codipront (Codeine and Phenyltoloxamine)
  Kimia Farma, Indonesia



• Codistat
  AC Farma, Peru



• Coditam (Codeine and Paracetamol)
  Kimia Farma, Indonesia



• Codol
  Confar, Portugal



• Eucalyptine le brun (Codeine and Eucalyptol)
  Tonipharm, France



• Eucalyptine (Codeine and Eucalyptol)
  Medgenix, Luxembourg



• Otodril (Codeine and Chlorpheniramine Maleate)
  Solitaire, India



• Pectoral
  Siphat, Tunisia



• Procodin (Codeine and Promethazine)
  DHA, Singapore



• Pulmoserum (Codeine and Guaiacol)
  Bailly-Creat, Tunisia



• Talgo Codeina (Codeine and Paracetamol)
  Ern, Spain



• Tercodin (Codeine and Terpin)
  Uphace, Vietnam



• Terdein F (Codeine and Terpin)
  Domesco, Vietnam



• Terpine Gonnon (Codeine and Terpin)
  Famar Lyon, Vietnam



• Neo-Codion (Codeine and Ascorbic Acid)
  Interdelta, Switzerland



• Neo-Codion (Codeine and Sulfogaiacol)
  Interdelta, Switzerland



• Bisoltus
  Boehringer Ingelheim, Spain



• Codeine HCl PCH
  Pharmachemie, Netherlands



• Codeine HCl ratiopharm
  ratiopharm, Netherlands



• Codicaps
  UCB, Germany



• Codicaps Kindersaft Neo (pediatric)
  UCB, Germany



• Eucalytux (Codeine and Sulfogaiacol)
  Tilman, Belgium



• Optipect
  UCB, Germany



• Toux-San Codeine
  Nycomed, Belgium



• Ac Cod PCH (Codeine and Acetylsalicylic Acid)
  Pharmachemie, Netherlands



• Ac Cod Ratiopharm (Codeine and Acetylsalicylic Acid)
  ratiopharm, Netherlands



• Acetaminophen and Codeine Phosphate (Codeine and Paracetamol)
  Actavis, United States; Amneal, United States; Duramed, United States; Hi-Tech, United States; Mallinckrodt, United States; Mikart, United States; Morton Grove, United States; Pharmaceutical Associates, United States; Ranbaxy, United States; Sandoz, United States; Teva USA, United States; Vintage, United States; Watson, United States



• Actacode
  Sigma, Australia



• Actadol Codeine (Codeine and Paracetamol)
  Mebiphar, Vietnam



• Actadol codeine 30 S (Codeine and Paracetamol)
  Phapharco, Vietnam



• Algicalm (Codeine and Paracetamol)
  Grünenthal, France



• Algisedal (Codeine and Paracetamol)
  Meda, France; Meda, Luxembourg



• Algocod (Codeine and Paracetamol)
  SMB, Belgium



• Analgiplus (Codeine and Paracetamol)
  Faes, Spain



• Antidol (Codeine and Paracetamol)
  Lek, Poland



• Ardinex (Codeine and Ibuprofen)
  Abbott, Finland; Abbott, Poland; Mundipharma, Sweden



• Ascodan (Codeine and Acetylsalicylic Acid)
  Polpharma, Poland



• Astefor (Codeine and Ibuprofen)
  Farmasierra, Spain



• Azur compositum (Codeine and Paracetamol)
  Steiner & Co, Germany



• Benylin mit Codein N (Codeine and Diphenhydramine)
  Janssen-Cilag, Switzerland



• Biragan Codein (Codeine and Paracetamol)
  Bidiphar, Vietnam



• Bromocodeina
  Menarini, United Arab Emirates; Menarini, Egypt; Menarini, Iraq; Menarini, Jordan; Menarini, Kuwait; Menarini, Lebanon; Menarini, Libya; Menarini, Morocco; Menarini, Qatar; Menarini, Saudi Arabia; Menarini, Sudan; Menarini, Syria; Menarini, Yemen



• Bromophar
  Qualiphar, Belgium; Qualiphar, Luxembourg



• Bronchialpastillen VA mit Codein
  Iromedica, Switzerland



• Bronchicum
  Aventis, Luxembourg; Cassella-med, Germany; Novum, Netherlands; Sanofi-Aventis, Bahrain



• Bronchodine
  Pharmacobel, Belgium



• Bronchosedal Codéine
  Janssen, Belgium; Janssen, Luxembourg



• Capital and Codeine Phosphate (Codeine and Paracetamol)
  Actavis, United States; Valeant, United States



• Capitole Bronchialpastillen mit Codein
  Iromedica, Switzerland



• Citodon (Codeine and Paracetamol)
  BioPhausia, Sweden



• Citodon forte (Codeine and Paracetamol)
  BioPhausia, Sweden



• Citodon minor (Codeine and Paracetamol)
  BioPhausia, Sweden



• Claradol Codéine (Codeine and Paracetamol)
  Bayer Santé Familiale, France



• Co-Becetamol für Kleinkinder (Codeine and Paracetamol (pediatric))
  Gebro, Switzerland



• Co-Becetamol (Codeine and Paracetamol)
  Gebro, Switzerland



• Cod Efferalgan (Codeine and Paracetamol)
  Bristol-Myers Squibb, Spain



• Co-Dafalgan (Codeine and Paracetamol)
  Bristol-Myers Squibb, Switzerland



• Codalgin (Codeine and Paracetamol)
  Fawns & McAllan, Australia; Sigma, New Zealand



• Codant
  Antigen, Ireland



• Codapane (Codeine and Paracetamol)
  Alphapharm, Australia



• Codedrill
  PF, Luxembourg; Pierre Fabre Médicament, France



• Codein Knoll
  Abbott, Switzerland



• Codein Slovakofarma
  Slovakofarma, Czech Republic; Zentiva, Slovakia



• Codeinã Fosfat
  Labormed Pharma, Romania



• Codeina Fosfato
  Roxfarma, Peru



• Codeinã Fosforicã
  Bio EEL, Romania; Fabiol, Romania; Magistra, Romania



• Codeinã
  Ozone Laboratories, Romania



• Codeine Linctus
  LCM, Malta



• Codeine Phosphate Injection USP
  Phebra, Australia



• Codeine Phosphate Mitsubishi Tanabe
  Tanabe Mitsubishi, Japan



• Codeine Phosphate Mylan
  Mylan Pharmaceutical, Japan



• Codeine Phosphate
  AFT, New Zealand; CP, Malta; Douglas, New Zealand; Fawns & McAllan, Australia; ICN, Romania; Lilly, United States; PSM, New Zealand; Ranbaxy, United States; Roxane, United States



• Codeine
  Isei, Japan



• Codéine
  Laboratoires Trianon, Canada



• Codeinefosfaat A
  Apothecon, Netherlands



• Codeinefosfaat PCH
  Pharmachemie, Netherlands



• Codeïnefosfaat ratiopharm
  ratiopharm, Netherlands



• Codeini phosphatis
  Alkaloid, Bosnia & Herzegowina; Alkaloid, Croatia (Hrvatska)



• Codeinsaft-CT
  CT Arzneimittel, Germany



• Codeintropfen-CT
  CT Arzneimittel, Germany



• Codeinum phosphoricum Berlin-Chemie
  Berlin-Chemie, Germany



• Codeinum phosphoricum Compren
  Desma, Germany



• Codeinum Phosphoricum
  Polfa Kutno, Poland



• Codeisan Jarabe
  Belmac, Spain



• Codeisan
  Belmac, Spain



• Codenfan
  Bouchara, France



• Codepect (Codeine and Guaifenesin)
  Mega Lifesciences, Vietnam



• Codi OPT
  Optimed, Germany



• Codical
  Sam-On, Israel



• Codicompren
  Desma, Germany



• Codinex
  Pinewood, Ireland



• Codipar (Codeine and Paracetamol)
  GlaxoSmithKline, Poland; Goldshield, United Kingdom



• Codipertussin
  Tussin, Germany



• Codis (Codeine and Acetylsalicylic Acid)
  Reckitt Benckiser, Ireland



• Codoliprane (Codeine and Paracetamol)
  Sanofi-Aventis, France



• Codoliprane enfant (Codeine and Paracetamol (pediatric))
  Sanofi-Aventis, France



• Codral (Codeine and Acetylsalicylic Acid)
  GlaxoSmithKline, Australia



• Co-Efferalgan (Codeine and Paracetamol)
  Bristol-Myers Squibb, Italy



• Combaren (Codeine and Diclofenac)
  Novartis, Germany



• Comfarol (Codeine and Paracetamol)
  Sandoz, Australia



• Compralgyl (Codeine and Paracetamol)
  Gifrer Barbezat, France



• Contraneural (Codeine and Paracetamol)
  Pfleger, Germany



• Coxumadol (Codeine and Paracetamol)
  Italfarmaco, Spain



• Cozeter (Codeine and Terpin)
  Saokim Pharma, Vietnam



• Dafalgan C (Codeine and Paracetamol)
  Bristol-Myers Squibb, Poland



• Dafalgan Codeine (Codeine and Paracetamol)
  Bristol-Myers Squibb, Belgium



• Dafalgan Codéine (Codeine and Paracetamol)
  Bristol-Myers Squibb, France



• Disprin Plus (Codeine and Acetylsalicylic Acid)
  Reckitt Benckiser, South Africa



• Docparacod (Codeine and Paracetamol)
  Docpharma, Belgium



• Dolaforte (Codeine and Paracetamol)
  Chemists, Australia



• Dolgesic Codeina (Codeine and Paracetamol)
  Novag, Spain



• Dolomedil (Codeine and Paracetamol)
  Almirall, Spain



• Dolviran (Codeine and Acetylsalicylic Acid)
  Meda, Germany; Meda, Luxembourg



• Dopagan Codein (Codeine and Paracetamol)
  Domesco, Vietnam



• Dr. Bähler Bronchialpastillen mit Codein
  Dr. Bähler, Switzerland



• Efferalgan Codeine (Codeine and Paracetamol)
  Bristol-Myers Squibb, Vietnam



• Efferalgan Codéine (Codeine and Paracetamol)
  Bristol-Myers Squibb, France



• Empacod (Codeine and Paracetamol)
  Nycomed Madaus, South Africa



• Eucalyptine (Codeine and Eucalyptol)
  Medgenix, Belgium



• Eucalyptine enfant (Codeine and Eucalyptol (pediatric))
  Medgenix, Belgium



• Fludan Codeina
  Faes, Spain



• Fludeten (Codeine and Paracetamol)
  Alter, Spain



• Fortamol (Codeine and Paracetamol)
  Nordic Drugs, Denmark



• Fosfat de Codeina
  Sintofarm, Romania; Terapia, Romania



• Fosfat de Codeinã
  Laropharm, Romania



• Galcodine
  Galen, Ireland



• Gaosédal Codéine (Codeine and Paracetamol)
  Merck Médication Familiale, France



• Gelocatil Codeina (Codeine and Paracetamol)
  Gelos, Spain



• Gelonida (Codeine and Paracetamol)
  Pfizer, Germany



• Gem Bronchialpastillen mit Codein
  Iromedica, Switzerland



• Glottyl
  Meda, Belgium; Meda, Luxembourg



• Hapacol codein Sui (Codeine and Paracetamol)
  HG.Pharm, Vietnam



• Histaverin
  Estedi, Spain



• Husten- und Bronchialsirup S
  Hänseler, Switzerland



• Ibucod (Codeine and Ibuprofen)
  Aspen Pharmacare Consumer, South Africa



• Ibuden (Codeine and Ibuprofen)
  Grupo Farma, Peru



• Inalpin (Codeine and Guaifenesin)
  Qualiphar, Belgium



• Infapain (Codeine and Paracetamol)
  Alliance, South Africa



• Injectio Codeine Phosphatis
  NBCD, Taiwan



• Iropect
  Iromedica, Switzerland



• Kapake (Codeine and Paracetamol)
  Galen, United Kingdom



• Klipal Codéine (Codeine and Paracetamol)
  Pierre Fabre Médicament, France



• Kodein Dak
  Nycomed, Denmark



• Kodein fosfat
  Alkaloid, Serbia; Fampharm, Serbia



• Kodein Recip
  Recip, Iceland; Recip, Sweden



• Kodein SAD
  Amgros, Denmark



• Kodein
  Nycomed, Norway



• Kodein (veterinary use)
  Nycomed Vet, Norway



• Kodeinijev Fosfat
  Alkaloid, Slovenia; Lekarna, Slovenia



• Kodipar (Codeine and Paracetamol)
  Nycomed, Denmark



• Korylan (Codeine and Paracetamol)
  Zentiva, Slovakia



• Lennon - Codeine Phosphate
  Aspen Pharmacare, South Africa



• Lindilane (Codeine and Paracetamol)
  Grünenthal, France



• Lonalgal (Codeine and Paracetamol)
  Boehringer Ingelheim, Greece



• Lonarid (Codeine and Paracetamol)
  Istituto De Angeli, Italy



• Lusadeina (Codeine and Paracetamol)
  Lusa, Peru



• Makatussin
  Nycomed, Germany



• Makatussin neue Formel
  Gebro, Switzerland



• Maku Bronchialpastillen mit Codein
  Iromedica, Switzerland



• Medamol (Codeine and Paracetamol)
  IFET, Greece



• Melrosum
  Aventis, Luxembourg; Novum, Netherlands



• Napacod (Codeine and Paracetamol)
  Adcock Ingram Pharmaceuticals, South Africa



• Nedolon (Codeine and Paracetamol)
  Merck, Germany



• Notusin
  Medea, Spain



• Nurofen Plus (Codeine and Ibuprofen)
  Reckitt Benckiser, Ireland; Reckitt Benckiser, New Zealand; Reckitt Benckiser, South Africa



• Optipyrin (Codeine and Paracetamol)
  Pfleger, Germany



• Padéryl
  Gerda, France



• Painamol Plus (Codeine and Paracetamol)
  Be-Tabs Pharmaceuticals, South Africa



• Panadeine (Codeine and Paracetamol)
  GlaxoSmithKline, Ireland; GlaxoSmithKline Consumer Healthcare, New Zealand; Sanofi-Aventis, Australia; Sanofi-Aventis, Singapore



• Panadol Codeine (Codeine and Paracetamol)
  GlaxoSmithKline, Belgium



• Panocod (Codeine and Paracetamol)
  Sanofi-Aventis, Sweden



• Paracetamol / Codeine A (Codeine and Paracetamol)
  Apothecon, Netherlands



• Paracetamol / Codeine Actavis (Codeine and Paracetamol)
  Actavis, Netherlands



• Paracetamol / Codeine Apotex (Codeine and Paracetamol)
  Apotex Europe, Netherlands



• Paracetamol / Codeine PCH (Codeine and Paracetamol)
  Pharmachemie, Netherlands



• Paracetamol / Codeine Ratiopharm (Codeine and Paracetamol)
  ratiopharm, Netherlands



• Paracetamol / Codeine Sandoz (Codeine and Paracetamol)
  Sandoz, Netherlands



• Paracetamol AL comp. (Codeine and Paracetamol)
  Aliud, Germany



• Paracetamol Codein (Codeine and Paracetamol)
  F.T. Pharma, Vietnam



• Paracétamol Codéine Almus (Codeine and Paracetamol)
  Almus, France



• Paracétamol Codéine Arrow (Codeine and Paracetamol)
  Arrow, France



• Paracétamol Codéine Biogaran (Codeine and Paracetamol)
  Biogaran, France



• Paracétamol Codéine CristerS (Codeine and Paracetamol)
  CristerS, France



• Paracétamol Codéine EG (Codeine and Paracetamol)
  EG Labo, France



• Paracétamol Codéine Mylan (Codeine and Paracetamol)
  Mylan, France



• Paracétamol Codéine Sandoz (Codeine and Paracetamol)
  Sandoz, France



• Paracétamol Codéine Teva (Codeine and Paracetamol)
  Teva Santé, France



• Paracetamol comp. Stada (Codeine and Paracetamol)
  Stada, Germany



• Paracetamol Codeine (Codeine and Paracetamol)
  Janssen, Belgium



• Paracotene (Codeine and Paracetamol)
  Multichem, New Zealand



• Paralgin (Codeine and Paracetamol)
  Weifa, Norway



• Paramax (Codeine and Paracetamol)
  Tauret, Slovakia



• Pectocalmine Junior (pediatric)
  Vifor, Switzerland



• Perduretas Codeina
  Nupel, Spain



• Pharmacieplus Bronchialpastillen mit Codein
  Iromedica, Switzerland



• Pinex Comp. (Codeine and Paracetamol)
  Actavis, Denmark



• Pinex Forte (Codeine and Paracetamol)
  Actavis, Norway



• Prodeine (Codeine and Paracetamol)
  Sanofi-Aventis, Australia



• Promethazine Hydrochloride and Codeine Phosphate (Codeine and Promethazine)
  Actavis, United States; Morton Grove, United States



• Pulmocodeina
  ECU, Ecuador



• ratio-Codeine
  ratiopharm, Canada



• ratio-Emtec-30 (Codeine and Paracetamol)
  ratiopharm, Canada



• Rekod
  Rekah, Israel



• Relcodin
  Pharbaco, Vietnam



• Resyl mit Codein (Codeine and Guaifenesin)
  Novartis Consumer Health, Austria



• Resyl plus (Codeine and Guaifenesin)
  Novartis Consumer Health, Switzerland



• Rotpunkt Apotheke Bronchialpastillen mit Codein
  Parcopharm, Switzerland



• Solpadol (Codeine and Paracetamol)
  Sanofi-Aventis, United Kingdom



• Spectrapain (Codeine and Paracetamol)
  Alliance, South Africa



• Tabellae Codeinae
  NBCD, Taiwan



• Talvosilen (Codeine and Paracetamol)
  Bene, Germany; Bene, Poland



• Tatanol Codein (Codeine and Paracetamol)
  PMP, Vietnam



• Termalgin Codeina (Codeine and Paracetamol)
  Novartis, Spain



• Thiocodin (Codeine and Codein)
  Unia, Poland



• Titretta (Codeine and Paracetamol)
  Berlin-Chemie, Germany



• Toseina
  Italfarmaco, Spain; ITF, Portugal



• Tossamin (Codeine and Noscapine)
  Novartis Consumer Health, Switzerland



• Toularynx
  Qualiphar, Belgium; Qualiphar, Luxembourg



• Triatec-30 (Codeine and Paracetamol)
  Laboratoires Trianon, Canada



• Tricodein Solco
  Solco, Ghana; Solco, Sudan



• Tricodein
  ICN Switzerland, United Arab Emirates; ICN Switzerland, Bahrain; ICN Switzerland, Cyprus; ICN Switzerland, Egypt; ICN Switzerland, Jordan; ICN Switzerland, Kuwait; ICN Switzerland, Lebanon; ICN Switzerland, Qatar; ICN Switzerland, Saudi Arabia; ICN Switzerland, Sudan; ICN Switzerland, Yemen



• Tussoret
  MaxMedic, Germany



• Tylenol with Codeine (Codeine and Paracetamol)
  McNeil Consumer Healthcare, Canada; Ortho-McNeil, United States



• Tylex (Codeine and Paracetamol)
  UCB Pharma, United Kingdom



• Ultracod (Codeine and Pracetamol)
  Zentiva, Poland; Zentiva, Slovakia



• Voltaren Plus (Codeine and Diclofenac)
  Novartis, Germany



• Zanidion (Codeine and Paracetamol)
  Domesco, Vietnam



• Zapain (Codeine and Paracetamol)
  Goldshield, United Kingdom



• Zürcher Bahnhof Apotheke Bronchialpastillen mit Codein
  Iromedica, Switzerland



• Codipront mono
  Mack, Luxembourg; Zuoz, Venezuela



• Codeine Contin
  Purdue Pharma, Canada



• Codeine Sulfate
  Roxane, United States

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
SPC	Summary of Product Characteristics (UK)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Bexon

Bexon may be available in the countries listed below.

Ingredient matches for Bexon

Clindamycin

Clindamycin dihydrogen phosphate (a derivative of Clindamycin) is reported as an ingredient of Bexon in the following countries:

• Colombia

Metronidazole

Metronidazole benzoate (a derivative of Metronidazole) is reported as an ingredient of Bexon in the following countries:

• Argentina

International Drug Name Search

Zolpimist

In the US, Zolpimist (zolpidem systemic) is a member of the drug class miscellaneous anxiolytics, sedatives and hypnotics and is used to treat Insomnia.

US matches:

• ZolpiMist


• Zolpimist Oral Spray

Ingredient matches for Zolpimist

Zolpidem

Zolpidem tartrate (a derivative of Zolpidem) is reported as an ingredient of Zolpimist in the following countries:

• United States

International Drug Name Search

Atropina Braun

Atropina Braun may be available in the countries listed below.

Ingredient matches for Atropina Braun

Atropine

Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Atropina Braun in the following countries:

• Spain

International Drug Name Search

Diphenoxylate and Atropine

Dosage Form: tablet
Diphenoxylate Hydrochloride

and Atropine Sulfate Cv, Tablets, USP

Diphenoxylate and Atropine Description

Each diphenoxylate hydrochloride and atropine sulfate tablet contains:

diphenoxylate hydrochloride	2.5 mg
atropine sulfate	0.025 mg

Diphenoxylate hydrochloride, an antidiarrheal, is ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride and has the following structural formula:

Atropine sulfate, an anticholinergic, is endo-(±)-α-(hydroxymethyl) benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1] oct-3-yl ester sulfate (2:1) (salt) monohydrate and has the following structural formula:

A subtherapeutic amount of atropine sulfate is present to discourage deliberate overdosage.

Inactive ingredients of diphenoxylate hydrochloride tablets include acacia, corn starch, magnesium stearate, sorbitol, sucrose, and talc.

Diphenoxylate and Atropine - Clinical Pharmacology

Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood. After a 5-mg oral dose of carbon-14 labeled diphenoxylate hydrochloride in ethanolic solution was given to three healthy volunteers, an average of 14% of the drug plus its metabolites was excreted in the urine and 49% in the feces over a four-day period. Urinary excretion of the unmetabolized drug constituted less than 1% of the dose, and diphenoxylic acid plus its glucuronide conjugate constituted about 6% of the dose. In a 16-subject crossover bioavailability study, a linear relationship in the dose range of 2.5 to 10 mg was found between the dose of diphenoxylate hydrochloride (given as diphenoxylate hydrochloride liquid) and the peak plasma concentration, the area under the plasma concentration-time curve, and the amount of diphenoxylic acid excreted in the urine. In the same study the bioavailability of the tablet compared with an equal dose of the liquid was approximately 90%. The average peak plasma concentration of diphenoxylic acid following ingestion of four 2.5-mg tablets was 163 ng/ml at about 2 hours, and the elimination half-life of diphenoxylic acid was approximately 12 to 14 hours.

In dogs, diphenoxylate hydrochloride has a direct effect on circular smooth muscle of the bowel that conceivably results in segmentation and prolongation of gastrointestinal transit time. The clinical antidiarrheal action of diphenoxylate hydrochloride may thus be a consequence of enhanced segmentation that allows increased contact of the intraluminal contents with the intestinal mucosa.

Indications and Usage for Diphenoxylate and Atropine

Diphenoxylate hydrochloride is effective as adjunctive therapy in the management of diarrhea.

Contraindications

Diphenoxylate hydrochloride is contraindicated in patients with:

1. Known hypersensitivity to diphenoxylate or atropine.


2. Obstructive jaundice.


3. Diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria.

Warnings

DIPHENOXYLATE HYDROCHLORIDE IS NOT AN INNOCUOUS DRUG AND DOSAGE RECOMMENDATIONS SHOULD BE STRICTLY ADHERED TO, ESPECIALLY IN CHILDREN. DIPHENOXYLATE HYDROCHLORIDE IS NOT RECOMMENDED FOR CHILDREN UNDER 2 YEARS OF AGE. OVERDOSAGE MAY RESULT IN SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH (SEE OVERDOSAGE). THEREFORE, KEEP THIS MEDICATION OUT OF THE REACH OF CHILDREN.

THE USE OF DIPHENOXYLATE HYDROCHLORIDE SHOULD BE ACCOMPANIED BY APPROPRIATE FLUID AND ELECTROLYTE THERAPY, WHEN INDICATED. IF SEVERE DEHYDRATION OR ELECTROLYTE IMBALANCE IS PRESENT, DIPHENOXYLATE HYDROCHLORIDE SHOULD BE WITHHELD UNTIL APPROPRIATE CORRECTIVE THERAPY HAS BEEN INITIATED. DRUG-INDUCED INHIBITION OF PERISTALSIS MAY RESULT IN FLUID RETENTION IN THE INTESTINE, WHICH MAY FURTHER AGGRAVATE DEHYDRATION AND ELECTROLYTE IMBALANCE.

DIPHENOXYLATE HYDROCHLORIDE SHOULD BE USED WITH SPECIAL CAUTION IN YOUNG CHILDREN BECAUSE THIS AGE GROUP MAY BE PREDISPOSED TO DELAYED DIPHENOXYLATE TOXICITY AND BECAUSE OF THE GREATER VARIABILITY OF RESPONSE IN THIS AGE GROUP.

Antiperistaltic agents may prolong and/or worsen diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic E. coli, Salmonella, Shigella), and pseudomembranous enterocolitis associated with broad-spectrum antibiotics. Antiperistaltic agents should not be used in these conditions.

In some patients with acute ulcerative colitis, agents that inhibit intestinal motility or prolong intestinal transit time have been reported to induce toxic megacolon. Consequently, patients with acute ulcerative colitis should be carefully observed and diphenoxylate hydrochloride therapy should be discontinued promptly if abdominal distention occurs or if other untoward symptoms develop.

Since the chemical structure of diphenoxylate hydrochloride is similar to that of meperidine hydrochloride, the concurrent use of diphenoxylate hydrochloride with monoamine oxidase (MAO) inhibitors may, in theory, precipitate hypertensive crisis.

Diphenoxylate hydrochloride should be used with extreme caution in patients with advanced hepatorenal disease and in all patients with abnormal liver function since hepatic coma may be precipitated.

Diphenoxylate hydrochloride may potentiate the action of barbiturates, tranquilizers, and alcohol. Therefore, the patient should be closely observed when any of these are used concomitantly.

Precautions

General

Since a subtherapeutic dose of atropine has been added to the diphenoxylate hydrochloride, consideration should be given to the precautions relating to the use of atropine. In children, diphenoxylate hydrochloride should be used with caution since signs of atropinism may occur even with recommended doses, particularly in patients with Down's syndrome.

Information for patients

INFORM THE PATIENT (PARENT OR GUARDIAN) NOT TO EXCEED THE RECOMMENDED DOSAGE AND TO KEEP DIPHENOXYLATE HYDROCHLORIDE OUT OF THE REACH OF CHILDREN AND IN A CHILD-RESISTANT CONTAINER. INFORM THE PATIENT OF THE CONSEQUENCES OF OVERDOSAGE, INCLUDING SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH. Diphenoxylate hydrochloride may produce drowsiness or dizziness. The patient should be cautioned regarding activities requiring mental alertness, such as driving or operating dangerous machinery. Potentiation of the action of alcohol, barbiturates, and tranquilizers with concomitant use of diphenoxylate hydrochloride should be explained to the patient. The physician should also provide the patient with other information in this labeling, as appropriate.

Drug interactions

Known drug interactions include barbiturates, tranquilizers, and alcohol. Diphenoxylate hydrochloride may interact with MAO inhibitors (see Warnings).

In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.

Carcinogenesis, mutagenesis, impairment of fertility

No long-term study in animals has been performed to evaluate carcinogenic potential. Diphenoxylate hydrochloride was administered to male and female rats in their diets to provide dose levels of 4 and 20 mg/kg/day throughout a three-litter reproduction study. At 50 times the human dose (20 mg/kg/day), female weight gain was reduced and there was a marked effect on fertility as only 4 of 27 females became pregnant in three test breedings. The relevance of this finding to usage of diphenoxylate hydrochloride in humans is unknown.

Pregnancy

Pregnancy Category C

Diphenoxylate hydrochloride has been shown to have an effect on fertility in rats when given in doses 50 times the human dose (see above discussion). Other findings in this study include a decrease in maternal weight gain of 30% at 20 mg/kg/day and of 10% at 4 mg/kg/day. At 10 times the human dose (4 mg/kg/day), average litter size was slightly reduced.

Teratology studies were conducted in rats, rabbits, and mice with diphenoxylate hydrochloride at oral doses of 0.4 to 20 mg/kg/day. Due to experimental design and small numbers of litters, embryotoxic, fetotoxic, or teratogenic effects cannot be adequately assessed. However, examination of the available fetuses did not reveal any indication of teratogenicity.

There are no adequate and well-controlled studies in pregnant women. Diphenoxylate hydrochloride should be used during pregnancy only if the anticipated benefit justifies the potential risk to the fetus.

Nursing mothers

Caution should be exercised when diphenoxylate hydrochloride is administered to a nursing woman, since the physicochemical characteristics of the major metabolite, diphenoxylic acid, are such that it may be excreted in breast milk and since it is known that atropine is excreted in breast milk.

Pediatric use

Diphenoxylate hydrochloride may be used as an adjunct to the treatment of diarrhea but should be accompanied by appropriate fluid and electrolyte therapy, if needed. DIPHENOXYLATE HYDROCHLORIDE IS NOT RECOMMENDED FOR CHILDREN UNDER 2 YEARS OF AGE. Diphenoxylate hydrochloride should be used with special caution in young children because of the greater variability of response in this age group. See Warnings and Dosage and Administration. In case of accidental ingestion by children, see Overdosage for recommended treatment.

Adverse Reactions

At therapeutic doses, the following have been reported; they are listed in decreasing order of severity, but not of frequency:

Nervous system: numbness of extremities, euphoria, depression, malaise/lethargy, confusion, sedation/drowsiness, dizziness, restlessness, headache.

Allergic: anaphylaxis, angioneurotic edema, urticaria, swelling of the gums, pruritus.

Gastrointestinal system: toxic megacolon, paralytic ileus, pancreatitis, vomiting, nausea, anorexia, abdominal discomfort.

The following atropine sulfate effects are listed in decreasing order of severity, but not of frequency: hyperthermia, tachycardia, urinary retention, flushing, dryness of the skin and mucous membranes. These effects may occur, especially in children.

THIS MEDICATION SHOULD BE KEPT IN A CHILD-RESISTANT CONTAINER AND OUT OF THE REACH OF CHILDREN SINCE AN OVERDOSAGE MAY RESULT IN SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH.

Drug Abuse and Dependence

Controlled substance

Diphenoxylate hydrochloride is classified as a Schedule V controlled substance by federal regulation. Diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine.

Drug abuse and dependence

In doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction.

Diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. At high doses it exhibits codeine-like subjective effects. The dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. The insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. A dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets, administered to humans for 40 to 70 days, produced opiate withdrawal symptoms. Since addiction to diphenoxylate hydrochloride is possible at high doses, the recommended dosage should not be exceeded.

Overdosage

RECOMMENDED DOSAGE SCHEDULES SHOULD BE STRICTLY FOLLOWED. THIS MEDICATION SHOULD BE KEPT IN A CHILD-RESISTANT CONTAINER AND OUT OF THE REACH OF CHILDREN, SINCE AN OVERDOSAGE MAY RESULT IN SEVERE, EVEN FATAL, RESPIRATORY DEPRESSION.

Diagnosis

Initial signs of overdosage may include dryness of the skin and mucous membranes, mydriasis, restlessness, flushing, hyperthermia, and tachycardia followed by lethargy or coma, hypotonic reflexes, nystagmus, pinpoint pupils, and respiratory depression. Respiratory depression may be evidenced as late as 30 hours after ingestion and may recur despite an initial response to narcotic antagonists. TREAT ALL POSSIBLE DIPHENOXYLATE HYDROCHLORIDE OVERDOSAGES AS SERIOUS AND MAINTAIN MEDICAL OBSERVATION FOR AT LEAST 48 HOURS, PREFERABLY UNDER CONTINUOUS HOSPITAL CARE.

Treatment

In the event of overdose, induction of vomiting, gastric lavage, establishment of a patent airway, and possibly mechanically assisted respiration are advised. In vitro and animal studies indicate that activated charcoal may significantly decrease the bioavailability of diphenoxylate. In noncomatose patients, a slurry of 100 g of activated charcoal can be administered immediately after the induction of vomiting or gastric lavage.

A pure narcotic antagonist (e.g., naloxone) should be used in the treatment of respiratory depression caused by diphenoxylate hydrochloride . When a narcotic antagonist is administered intravenously, the onset of action is generally apparent within two minutes. It may also be administered subcutaneously or intramuscularly, providing a slightly less rapid onset of action but a more prolonged effect.

To counteract respiratory depression caused by diphenoxylate hydrochloride overdosage, the following dosage schedule for the narcotic antagonist naloxone hydrochloride should be followed:

Adult dosage

An initial dose of 0.4 mg to 2 mg of naloxone hydrochloride may be administered intravenously. If the desired degree of counteraction and improvement in respiratory functions is not obtained, it may be repeated at 2- to 3-minute intervals. If no response is observed after 10 mg of naloxone hydrochloride has been administered, the diagnosis of narcotic-induced or partial narcotic-induced toxicity should be questioned. Intramuscular or subcutaneous administration may be necessary if the intravenous route is not available.

Children

The usual initial dose in children is 0.01 mg/kg body weight given I.V. If this dose does not result in the desired degree of clinical improvement, a subsequent dose of 0.1 mg/kg body weight may be administered. If an I.V. route of administration is not available, naloxone hydrochloride may be administered I.M. or S.C. in divided doses. If necessary, naloxone hydrochloride can be diluted with sterile water for injection.

Following initial improvement of respiratory function, repeated doses of naloxone hydrochloride may be required to counteract recurrent respiratory depression. Supplemental intramuscular doses of naloxone hydrochloride may be utilized to produce a longer-lasting effect.

Since the duration of action of diphenoxylate hydrochloride is longer than that of naloxone hydrochloride, improvement of respiration following administration may be followed by recurrent respiratory depression. Consequently, continuous observation is necessary until the effect of diphenoxylate hydrochloride on respiration has passed. This effect may persist for many hours. The period of observation should extend over at least 48 hours, preferably under continuous hospital care. Although signs of overdosage and respiratory depression may not be evident soon after ingestion of diphenoxylate hydrochloride, respiratory depression may occur from 12 to 30 hours later.

Diphenoxylate and Atropine Dosage and Administration

DO NOT EXCEED RECOMMENDED DOSAGE.

Adults

The recommended initial dosage is two diphenoxylate hydrochloride tablets four times daily . Most patients will require this dosage until initial control has been achieved, after which the dosage may be reduced to meet individual requirements. Control may often be maintained with as little as 5 mg (two tablets) daily.

Clinical improvement of acute diarrhea is usually observed within 48 hours. If clinical improvement of chronic diarrhea after treatment with a maximum daily dose of 20 mg of diphenoxylate hydrochloride is not observed within 10 days, symptoms are unlikely to be controlled by further administration.

Children

Diphenoxylate hydrochloride is not recommended in children under 2 years of age and should be used with special caution in young children (see Warnings and Precautions). The nutritional status and degree of dehydration must be considered. Do not use diphenoxylate hydrochloride tablets for children under 13 years of age .

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

How is Diphenoxylate and Atropine Supplied

Tablets — round, white, with SEARLE debossed on one side and 61 on the other side and containing 2.5 mg of diphenoxylate hydrochloride and 0.025 mg of atropine sulfate, supplied as:

NDC Number	Size
59762-1061-1	bottle of 100

LAB-0517-1.0

June 2011

PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label

NDC 59762-1061-1

100 Tablets

GREENSTONE® BRAND

diphenoxylate

hydrochloride

and atropine

sulfate tablets,

USP

CV

2.5 mg/0.025 mg*

Rx only

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE  diphenoxylate hydrochloride and atropine sulfate  tablet

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 59762-1061 Route of Administration ORAL DEA Schedule CV

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Diphenoxylate Hydrochloride (Diphenoxylate) Diphenoxylate Hydrochloride 2.5 mg Atropine Sulfate (Atropine) Atropine Sulfate 0.025 mg

Inactive Ingredients Ingredient Name Strength acacia   starch, corn   magnesium stearate   sorbitol   sucrose   talc

Product Characteristics Color WHITE Score no score Shape ROUND Size 6mm Flavor Imprint Code SEARLE;61 Contains

Packaging # NDC Package Description Multilevel Packaging 1 59762-1061-1 100 TABLET In 1 BOTTLE None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA authorized generic	NDA012462	09/15/1960

Labeler - Greenstone LLC (825560733)

Establishment
Name	Address	ID/FEI	Operations
Pfizer Pharmaceuticals LLC		193684656	MANUFACTURE

Establishment
Name	Address	ID/FEI	Operations
Mallinckrodt Inc. Pharmaceuticals Group		163205300	API MANUFACTURE

Revised: 06/2011Greenstone LLC

More Diphenoxylate and Atropine resources

• Diphenoxylate and Atropine Side Effects (in more detail)
• Diphenoxylate and Atropine Dosage
• Diphenoxylate and Atropine Use in Pregnancy & Breastfeeding
• Drug Images
• Diphenoxylate and Atropine Drug Interactions
• Diphenoxylate and Atropine Support Group
• 23 Reviews for Diphenoxylate and Atropine - Add your own review/rating

Compare Diphenoxylate and Atropine with other medications

• Diarrhea

Firstein

Firstein may be available in the countries listed below.

Ingredient matches for Firstein

Cefozopran

Cefozopran hydrochloride (a derivative of Cefozopran) is reported as an ingredient of Firstein in the following countries:

• Japan

International Drug Name Search

Bute

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Bute

Phenylbutazone

Phenylbutazone is reported as an ingredient of Bute in the following countries:

• Australia


• Italy


• United States

Phenylbutazone sodium salt (a derivative of Phenylbutazone) is reported as an ingredient of Bute in the following countries:

• Italy

International Drug Name Search

Diclo-Divido

Diclo-Divido may be available in the countries listed below.

Ingredient matches for Diclo-Divido

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclo-Divido in the following countries:

• Germany

International Drug Name Search

Tamokadin

Tamokadin may be available in the countries listed below.

Ingredient matches for Tamokadin

Tamoxifen

Tamoxifen citrate (a derivative of Tamoxifen) is reported as an ingredient of Tamokadin in the following countries:

• Germany

International Drug Name Search

Centrac

Centrac may be available in the countries listed below.

Ingredient matches for Centrac

Prazepam

Prazepam is reported as an ingredient of Centrac in the following countries:

• Greece

International Drug Name Search

Hexétidine

Hexétidine may be available in the countries listed below.

Ingredient matches for Hexétidine

Hexetidine

Hexétidine (DCF) is also known as Hexetidine (Rec.INN)

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Differin Pads

Pronunciation: ADE-ah-PAH-leen
Generic Name: Adapalene
Brand Name: Differin

Differin Pads are used for:

Treating acne. It may also be used for other conditions as determined by your doctor.

Differin Pads are a retinoid-like medicine. It works by decreasing acne formation.

Do NOT use Differin Pads if:

• you are allergic to any ingredient in Differin Pads

Contact your doctor or health care provider right away if any of these apply to you.

Before using Differin Pads:

Some medical conditions may interact with Differin Pads. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have eczema or sunburn

Some MEDICINES MAY INTERACT with Differin Pads. Because little, if any, of Differin Pads are absorbed into the blood, the risk of it interacting with another medicine is low.

Ask your health care provider if Differin Pads may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Differin Pads:

Use Differin Pads as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Differin Pads are for external use only. Avoid contact with the eyes, lips, angles of the nose, and mouth. Exposure of Differin Pads to the eye may cause swelling, redness, and irritation.


• Do not apply Differin Pads to cuts, abrasions, eczema, or sunburned skin. If you are sunburned, do not use this product on the sunburned area until your skin has completely recovered.


• Before applying Differin Pads, clean the area to be treated with mild soap or soapless cleanser and gently dry.


• Remove the pledget from the foil just before using. Throw the pledget away after a single use.


• Apply a thin film of Differin Pads to the affected area, using enough to lightly cover the entire area. Rub in gently. Wash your hands immediately after using Differin Pads.


• If you miss a dose of Differin Pads, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Differin Pads.

Important safety information:

• Differin Pads may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Differin Pads. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.


• Acne may worsen in the early stages of taking Differin Pads. This is due to the action of Differin Pads on unseen lesions. It may take 8 to 12 weeks before you see the full benefit.


• Do not use any other medicines or products on your skin unless your doctor instructs you otherwise.


• Wind and cold temperatures may irritate the affected skin.


• Differin Pads should be used with extreme caution in CHILDREN younger than 12 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Differin Pads while you are pregnant. It is not known if Differin Pads are found in breast milk. If you are or will be breast-feeding while you use Differin Pads, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Differin Pads:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Acne; dry skin; feeling of warmth; irritation; itching; peeling; redness; scaling; sunburn; temporary burning or stinging.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blistering; crusting; excessive redness or peeling; swelling.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Differin side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of Differin Pads:

Store Differin Pads at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not use the pledget if the seal is broken. Do not store in the bathroom. Keep Differin Pads out of the reach of children and away from pets.

General information:

• If you have any questions about Differin Pads, please talk with your doctor, pharmacist, or other health care provider.


• Differin Pads are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Differin Pads. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Differin resources

• Differin Side Effects (in more detail)
• Differin Use in Pregnancy & Breastfeeding
• Differin Drug Interactions
• Differin Support Group
• 14 Reviews for Differin - Add your own review/rating

Compare Differin with other medications

• Acne